Psilocybin, a hallucinogenic compound found in so-called magic mushrooms, has been attracting interest in the field of mental health for several years. While it was once not only stigmatized but also directly associated with psychedelic culture, it is now the focus of several serious scientific studies aimed at discovering its therapeutic potential. Can psilocybin truly revolutionize mental health in France?
What is psilocybin?
By definition, it is a naturally occurring hallucinogenic alkaloid found in several species of mushrooms in the genus Psilocybe. When ingested, it is converted into psilocin by the body. This new substance is an active compound that binds to and acts primarily on serotonin receptors in the brain. As a result, the user will experience altered perception, emotions, and cognition, producing hallucinogenic effects .
While the issue of psilocybin in France appears divisive, researchers’ interest in psilocybin extends beyond its psychotropic properties. According to some clinical trials, it could have a significant impact on certain mental health disorders, such as some addictions, anxiety disorders, and even treatment-resistant depression.
Promising results of psilocybin for depression
Statistically, one in five people in France will suffer from depression at some point in their lives. Unfortunately, traditional treatments based on antidepressants and therapies fail to alleviate the symptoms for a portion of the population. In this context, psilocybin presents itself as a potential solution.
Indeed, clinical trials in the USA and the UK have shown that controlled doses of psilocybin could lead to a rapid and even lasting reduction in the symptoms of depression. This explains the growing interest in this substance in France, where depression is a major public health issue.
A reduction in anxiety among terminally ill patients
Faced with the prospect of death, many patients exhibit signs of existential angst . These signs are not always alleviated by conventional treatments. Some studies show that administering psilocybin under medical supervision is effective in reducing this anxiety. It promotes emotional reappraisal and a more serene acceptance of one’s life circumstances. According to trials conducted at Johns Hopkins University, a significant percentage of patients demonstrated a sense of inner peace and a lasting reduction in anxiety after one or two supervised sessions.
Psilocybin is effective against addictions
Addictions affect many people in France, whether it be alcohol, nicotine, or other substances. Despite the large number of treatments available, success rates sometimes remain mixed. However, psilocybin could offer a new approach.
Clinical studies suggest that psilocybin-assisted therapy sessions combined with psychological counseling can help patients overcome their addiction. One trial involving long-term smokers found that 80% of participants quit smoking six months after receiving controlled doses of psilocybin. This rate is significantly higher than that achieved with nicotine replacement therapy or behavioral therapy.
What about the legality of psilocybin in France?
Psilocybin is still classified as a narcotic in France. The reluctance is justified, on the one hand, by the hallucinogenic nature of the substance, and on the other hand, by the lack of clinical data regarding its long-term effects.
Thus, like most European countries, France is cautious regarding the potential legalization or even authorization of its therapeutic use. However, following increasing pressure and growing scientific evidence supporting its efficacy, legislative changes are possible in the coming years, subject to certain conditions.
